Dr. Joan Mannick, Co-Founder, Chief Medical Officer of resTORbio, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, discusses their lead program that is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.

Listen to more health-related stories and research updates at www.hpr.fm

свернуть